Zymeworks Inc. (ZYME)
NASDAQ: ZYME · Real-Time Price · USD
12.47
+0.10 (0.81%)
At close: Jun 27, 2025, 4:00 PM
13.10
+0.63 (5.05%)
After-hours: Jun 27, 2025, 7:04 PM EDT
Zymeworks Employees
As of December 31, 2024, Zymeworks had 286 total employees, including 280 full-time and 6 part-time employees. The number of employees increased by 8 or 2.88% compared to the previous year.
Employees
286
Change (1Y)
8
Growth (1Y)
2.88%
Revenue / Employee
$326,517
Profits / Employee
-$397,476
Market Cap
868.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ZYME News
- 16 days ago - Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade) - Seeking Alpha
- 4 weeks ago - Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer - GlobeNewsWire
- 5 weeks ago - Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences - GlobeNewsWire
- 5 weeks ago - Zymeworks Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 5 weeks ago - Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference - GlobeNewsWire
- 7 weeks ago - Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline - Seeking Alpha